iRhythm Technologies (IRTC) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business Overview and Market Opportunity

• Focused on transforming cardiac arrhythmia diagnosis with a 14-day wearable biosensor and AI-driven analysis, supported by nearly 40 peer-reviewed publications and high physician agreement rates.

• Zio platform leverages 111 patented wearable biosensors, FDA-cleared AI, and a scalable digital platform for ECG detection and reporting.

• Competitive advantages include clinical accuracy, workflow integration (notably with Epic), and leadership in long-term continuous monitoring (LTCM) with over 70% market share.

• Achieved over 2 million annual reports and nearly 10 million total, with only 30% market penetration, indicating significant growth potential.

• Patch-based technology is expected to become the standard of care, with a large untapped market in primary care and international expansion underway, targeting a $1B+ TAM and 5M+ tests in EMEA and APAC.

Growth Strategy and Primary Care Expansion

• Aggressively moving up the care pathway into primary care, now seeing over 20% of prescriptions from this channel in 2024.

• Over 50% of IDNs now have prescribing primary care physicians, and partnerships with large national networks are expanding reach.

• Near-term topline growth driven by PCP channel expansion, new technologies, and proactive monitoring programs.

• Integration with Epic's Aura platform streamlines workflow, reduces integration time by 75%, and increases accessibility for new accounts.

• Artificial intelligence underpins core capabilities, enabling prediction, insight generation, and adjacent market opportunities.

Product Innovation and Pipeline

• Developing a new MCT product for FDA submission in Q3 2025, targeting a 2026 launch to close competitive gaps and gain share in a $1B+ market.

• Strategic technology licensing with BioIntelliSense to add multiparameter sensing and expand platform capabilities.

• Multi-modal sensing platform in development via BioIntelliSense partnership, enabling monitoring for sleep, hypertension, and other conditions on a single device.

• International expansion includes launches in the UK, four EU countries, and regulatory approval in Japan, with reimbursement expected by mid-2025.

• Expansion beyond arrhythmia into adjacent markets like sleep disease and hypertension, leveraging the same platform and AI capabilities.